drugset
drugset / Trial / NCT03317717

Pharmacodynamic and Safety of MEDITOXIN® in Healthy Male Volunteers

NCT03317717 ↗

Phase 1 Completed 25 enrolled Medy-Tox
RandomizedParallel-groupQuadruple-blindBasic science

Summary

This study will determine the pharmacodynamic and safety of MEDITOXIN® in healthy male volunteers.

Timeline

Start
2017-10-12
Primary completion
2018-01-30
Completion
2018-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 2 iu —
Subject Botulinum toxin type A Protein / enzyme biologic 5 iu —
Subject Botulinum toxin type A Protein / enzyme biologic 10 iu —
Subject Botulinum toxin type A Protein / enzyme biologic 20 iu —
Subject Botulinum toxin type A Protein / enzyme biologic 30 iu —
Subject Meditoxin Protein / enzyme biologic 2 iu Intramuscular
Subject Meditoxin Protein / enzyme biologic 5 iu Intramuscular
Subject Meditoxin Protein / enzyme biologic 10 iu Intramuscular
Subject Meditoxin Protein / enzyme biologic 20 iu Intramuscular
Subject Meditoxin Protein / enzyme biologic 30 iu Intramuscular

Indications

No indication recorded.